Fischer 344 rats (60/sex/group) were given daily subcutaneou s injections of recombinant human parathyroi d hormone (PTH)(1-34) for 2 years at doses of 0, 5, 30, or 75 μg/kg. Treatment caused substantial increases in bone mass consistent with the known pharmacologic effects of once-daily administration. As determined by quantitative computed tomography (QCT) and histomorphometry, bone mass was markedly increased. Substantial new bone formation resulted in a large decrease in marrow space accompanied by altered bone architecture. Bone proliferative lesions were observed in all PTH(1-34)-treated groups. Osteosarcoma occurred in 3, 21, and 31 male rats and in 4, 12, and 23 female rats in the 5-, 30-, and 75- μg/kg treatment groups, respectively. Focal osteoblast hyperplasia, osteoma, and osteoblastoma were much less frequent. Although the specific cellular or molecular mechanisms responsible for the rat bone tumors have not been fully elucidated, the data suggest that these lesions resulted from the long duration of treatment and the exaggerated pharmacologic response of the rat skeleton to daily treatment with PTH(1-34). Important differences between the rat study and clinical use in adult humans suggest that the increased incidence of bone neoplasia in rats treated for 2 years is likely not predictive of an increased risk of bone cancer in skeletally mature adult humans being given PTH(1-34) for a limited period of time in the treatment of osteoporosis.
Bagi CM, Wilkie D., Georgelos K., Williams D., Bertolini D. (1997). Morphological and structural characteristics of the proximal femur in human and rat. Bone21: 261—267.
2.
Baumann BD, Wronski TJ (1995). Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone16(2): 247—253.
3.
Boorman GA, Eustis SL, Elwell MR, Montgomery CA Jr, Mackenzie WF (eds). (1990). Bones, joint, and synovia . In: Pathology of the Fischer Rat, Leininger JR, Riley MGI (eds). Academic Press, San Diego, California , pp 209—226.
4.
Brommage R., Hotchkiss CE, Lees CJ, Stancill MW, Hock JM, Jerome CP (1999). Daily treatment with human recombinant parathyroid hormone (1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab84: 3757—3763.
5.
Burr DB, Hirano T., Turner CH, Hotchkiss C., Brommage R., Hock JM ( 2001). Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys . J Bone Miner Res16: 157—165.
6.
Capen CC (1996). Hormonal imbalances and mechanisms of chemical injury of the thyroid gland. In: Endocrine System, Jones TC, Mohr U (eds). Springer, Berlin, pp 217—238.
7.
Capen CC (1997). Mechanistic data and risk assessment of selected toxic end points of the thyroid gland. Toxicol Pathol25(1): 39—48.
8.
Compston JE (2001). Sex steroids and bone. Physiol Rev81: 419—447.
9.
Cosman F., Lindsay R. (1998). Is parathyroid hormone a therapeutic option for osteoporosis ? A review of the clinical evidence. Calcif Tissue Int62(6): 475—480.
10.
Curran PG, DeGroot LJ (1991). The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland. Endocr Rev12(2): 135— 150.
11.
Dempster DW, Cosman F., Parisien M., Shen V., Lindsay R. (1993). Anabolic actions of parathyroi d hormone on bone . Endocr Rev14(6): 690—709.
12.
Dobnig H., Turner RT (1995). Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology136: 3632—3638.
13.
Dorfman HD, Czerniak B. (1998). Benign osteoblastic tumors. In: Bone Tumors, Mosby, Saint Louis, Missouri, pp 85—252.
14.
Ejersted C. , Andreassen TT, Oxlund H., Jorgensen PH, Bak B., Haggblad J., Torring O., Nilsson MHL (1993). Human parathyroid hormone (1—34) and (1—84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res8(9): 1097—1101.
15.
Ekman L., Hansson E., Havu N., Carlsson E., Lundberg C. (1985). Toxicological studies on omeprazole. Scand J Gastroenterol20 Suppl 108: 53—69.
16.
Fechner RE, Mills SE (1993). Osseous lesions. In: Tumors of the Bones and Joints, Armed Forces Institute of Pathology , Washington, pp 25—77.
17.
Garrahan NJ , Mellish RWE, Compston JE (1986). A new method for the two-dimensional analysis of bone structure in human iliac crest biopsies. J Micros143: 341—349.
18.
Gasser JA, Jerome CP (1992). Parathyroid hormone: A cure for osteoporosis?Triangle31: 111—121.
19.
Hansson T., Roos B. ( 1986). Age changes in the bone mineral density of the lumbar spine in normal women. Calcif Tissue Int38: 249—251.
20.
Jerome CP (1994). Anabolic effect of high doses of human parathyroid hormone (1-38) in mature intact female rats. J Bone Miner Res9(6): 933— 942.
21.
Jerome CP, Burr DB, Van Bibber T., Hock JM, Brommage R. (2001). Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomologous monkeys (Macaca fascicularis). Bone28(2): 150— 159.
22.
Jilka RL, Weinstein RS, Bellido T., Roberson P., Parfitt AM, Manolagas SC (1999). Increased boneformation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest104: 439—446.
23.
Kimmel DB (1991). Quantitative histologic changes in the proximal tibial growth cartilage of aged female rats. Cell Mater Suppl1: 11—18.
24.
Kimmel DB (1996). Animal models for in vivo experimentation in osteoporosis research. In: Osteoporosis, Marcus R, Feldman D, Kelsey J (eds). Academic Press, San Diego, California, pp 671—690.
25.
Kodel RL, Haskin MG, Shaw GW, Gaylor DW (1983). Chronic: A SAS procedure for statistical analysis ofcarcinogenesi s studies. J Statist Comput Simul16: 287—310.
26.
Laib A., Ruegsegger P. (1999). Calibration of trabecular bone structure measurements of in vivo 3D peripheral quantitative computed tomography with 28 um resolution microcomputed tomography. Bone24: 35—39.
27.
Li XJ, Jee WSS, Ke HZ, Mori S., Akamine T. (1991). Age—related changes of cancellous and cortical bone histomorphometry in female Sprague-Dawley rats. Cells Mater Suppl 1: 25—35.
28.
Lin KK, Rahman MA (1998). Overall false positive rates in tests for linear trend in tumor incidence in animal carcinogenicity studies of new drugs. J Biopharm Stat8(1): 1—15.
29.
Long PH, Leininger JR, Nold JB, Lieuallen WG (1993). Proliferative lesions of bone, cartilage, tooth, and synovium in rats. In: Guides for Toxicologic Pathology, STP/ARP/AFIP, Washington, DC, pp 1—18.
30.
Massoomi F. , Savage J., Destache CJ (1993). Omeprazole: A comprehensive review. Pharmacotherapy13(1): 46—49.
31.
McClain RM (1989). The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: Implications for thyroid gland neoplasia. Toxicol Pathol17: 294—306.
32.
Mierke DF, Pellegrini M. (1999). Parathyroid hormone and parathyroid hormone-related protein: Model systems for the development of an osteoporosi s therapy. Current Pharmaceut Des5: 21—36.
33.
Mosekilde L. , Danielsen CC, Sogaard CH, McOsker JE, Wronski TJ (1995). The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength assessed in a sexually mature, ovariectomized rat model. Bone16(2): 223—230.
34.
Muller R., Hildebrand T., Ruegsegger P. (1994). Non-invasive bone biopsy: A new method to analyze and display the 3D structure of trabecular bone. Phys Med Biol39: 145—164.
35.
Neer RM, Arnaud CD, Zanchetta JR, Prince R., Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Shalom S., Genant HK, Wang O., Mitlak BH (2001). Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med344: 1434—1441.
36.
Oxlund H., Ejersted C., Andreassen TT, Torring O., Nilsson MHL (1993). Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum. Calcif Tissue Int53(6): 394— 399.
37.
Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H., Meunier PJ, Ott SM, Recker RR (1987). Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res2: 595—610.
38.
Peto R., Pike MC, Day NE, Gray RG, Lee PN, Parish S., Peto J., Richards S., Wahrendorf J. (1980). Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal exsperiments. In: Long Term and Short Term Screening Assays for Carcinogens: A Critical Appraisal , International Agency for Research on Cancer Monographs , Lyon, France, pp 311—426.
Qi H., Li M., Wronski TJ (1995). A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. J. Bone Miner Res10: 948—955.
41.
Recker RR, Davies KM, Hinders SM, Heaney RP, Stegman MR, Kimmel DB (1992). Bone gain in young adult women. JAMA268: 2403—2408.
42.
Recker RR, Kimmel DB, Parfitt AM, Davies KM, Keshawarz N., Hinders S. (1988). Static and tetracycline-based bone histomorphometri c data from 34 normal postmenopausal females. J Bone Miner Res3(2): 133—143.
43.
Sato M. (1995). Comparative x-ray densitometry of bones from ovariectomized rats. Bone17: 157S—162S.
44.
Sato M., Schmidt A., MaL., Smith S., Rowley E., Cole H., Westmore M. (2001). Dose-dependent PTH effects in young, intact female rats after 9 months of treatment. J Bone Miner Res.16(Suppl 1): 5292.
45.
Sato M., Westmore M., Clendenon J., Smith S., Hannum B., Zeng GQ, Brommage R., Turner CH (2000). Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomologous macaques. Osteoporos Int11 (10): 871—880.
46.
Sato M., Zeng GQ, Turner CH (1997). Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats. Endocrinology138(10): 4330—4337.
47.
Schmidt IU, Dobnig H., Turner RT (1995). Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology136(11): 5127—5134.
48.
Whitfield JF , Morley P., Willick GE (1999). The bone-building action of the parathyroid hormone. Drugs Aging15: 117—129.
49.
Wronski TJ, Yen CF (1994). Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone15(1): 51—58.
50.
Zanchetta JR , Bodago C., Ferretti JL, Wang O., Sato M., Gaich G. (2001). Effects of recombinantparathyroi d hormone (1-34) on cortical bone strength indices as assessed by peripheral quantitative computed tomography. Bone28(Suppl): S86.
